Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F11%3A00002516" target="_blank" >RIV/00023001:_____/11:00002516 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.2215/CJN.00270111" target="_blank" >http://dx.doi.org/10.2215/CJN.00270111</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2215/CJN.00270111" target="_blank" >10.2215/CJN.00270111</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes

Popis výsledku v původním jazyce

Background and objectives Renal transplant recipients with pre-existing diabetes (PD) have reduced graft survival and increased risk of mortality and ischemic heart disease compared with nondiabetic transplant recipients. To assess the effect of belatacept in this high-risk group, we evaluated outcomes of the subpopulation with PD from previously published BENEFIT and BENEFIT-EXT trials. Design, setting, participants, & measurements A post hoc analysis evaluated pooled data from BENEFIT (living donors or standard criteria donors) and BENEFIT-EXT (extended criteria donors). Patients were randomized to receive cyclosporine or a more intensive (MI) or less intensive (LI) belatacept regimen. Results Of 1209 intent-to-treat patients, 336 had PD. At 12 months, the belatacept LI arm demonstrated a numerically higher rate of patients surviving with a functioning graft (90.4% MI [103 of 114], 92.8% LI [90 of 971, and 80.8% cyclosporine [101 of 125]), and fewer serious adverse events than cyclos

Název v anglickém jazyce

Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes

Popis výsledku anglicky

Background and objectives Renal transplant recipients with pre-existing diabetes (PD) have reduced graft survival and increased risk of mortality and ischemic heart disease compared with nondiabetic transplant recipients. To assess the effect of belatacept in this high-risk group, we evaluated outcomes of the subpopulation with PD from previously published BENEFIT and BENEFIT-EXT trials. Design, setting, participants, & measurements A post hoc analysis evaluated pooled data from BENEFIT (living donors or standard criteria donors) and BENEFIT-EXT (extended criteria donors). Patients were randomized to receive cyclosporine or a more intensive (MI) or less intensive (LI) belatacept regimen. Results Of 1209 intent-to-treat patients, 336 had PD. At 12 months, the belatacept LI arm demonstrated a numerically higher rate of patients surviving with a functioning graft (90.4% MI [103 of 114], 92.8% LI [90 of 971, and 80.8% cyclosporine [101 of 125]), and fewer serious adverse events than cyclos

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical journal of the American Society of Nephrology

ISSN

1555-9041

e-ISSN

—

Svazek periodika

6

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

2696-2704

Kód UT WoS článku

000296821300022

EID výsledku v databázi Scopus

—